Search hospitals
>
Tennessee
>
Nashville
Vanderbilt University Medical Center
Claim this profile
Nashville, Tennessee 37203
Global Leader in Cancer
Global Leader in Heart Failure
Conducts research for Obesity
Conducts research for Diabetes
Conducts research for Lung Cancer
1944 reported clinical trials
209 medical researchers
Summary
Vanderbilt University Medical Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Heart Failure, Obesity, Diabetes, Lung Cancer and other specialties. Vanderbilt University Medical Center is involved with conducting 1,944 clinical trials across 2,124 conditions. There are 209 research doctors associated with this hospital, such as Scott Borinstein, M.D., Italo Biaggioni, MD, Michael Gibson, and Elizabeth J. Davis.
Area of expertise
Cancer
Vanderbilt University Medical Center has run 105 trials for Cancer. Some of their research focus areas include:
Heart Failure
Vanderbilt University Medical Center has run 85 trials for Heart Failure. Some of their research focus areas include:
Top PIs
Scott Borinstein, M.D.
Vanderbilt University/Ingram Cancer Center
8 years of reported clinical research
Italo Biaggioni, MD
Autonomic Dysfunction Center/ Vanderbilt University Medical Center
8 years of reported clinical research
Michael Gibson
Vanderbilt University/Ingram Cancer Center
5 years of reported clinical research
Elizabeth J. Davis
Vanderbilt University/Ingram Cancer Center
6 years of reported clinical research
Clinical Trials running at Vanderbilt University Medical Center
Colorectal Cancer
Prader-Willi Syndrome
Breast Cancer
Ovarian Cancer
Cancer
Parkinson's Disease
Age-Related Macular Degeneration
Multiple Myeloma
Carcinoid Tumor
Diaphyseal Tibial Fractures
Fruquintinib
for Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
Recruiting
3 awards
Phase 4
6 criteria
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting
2 awards
Phase 3
Sotorasib + Panitumumab + FOLFIRI
for Colorectal Cancer
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Recruiting
2 awards
Phase 3
3 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vanderbilt University Medical Center?
Vanderbilt University Medical Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Heart Failure, Obesity, Diabetes, Lung Cancer and other specialties. Vanderbilt University Medical Center is involved with conducting 1,944 clinical trials across 2,124 conditions. There are 209 research doctors associated with this hospital, such as Scott Borinstein, M.D., Italo Biaggioni, MD, Michael Gibson, and Elizabeth J. Davis.
Where is Vanderbilt University Medical Center located?
**Vanderbilt University Medical Center** - **Address:** 1211 Medical Center Dr, Nashville, TN 37232 - **Parking:** Available at the Central Garage, 2120 Dixie Place, Nashville, TN 37232. Parking is free.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Vanderbilt University Medical Center, contact customer service for help with applications for community and government-sponsored programs, financial assistance policy explanations, and payment plan options. For inquiries about your Explanation of Benefits (EOB), referrals, medical claims, or bills, contact Insurance Representative Kristina Miller at Kristina.Miller@vumc.org or 615-343-4688. For insurance-related questions, use the contact form on the Office of Financial Aid website or call 615-322-3591, Monday - Friday, 8:00am - 5:00pm CST. The financial counselor at Vanderbilt Children's Hospital can assist with coverage questions, financial and insurance issues, and identify financial assistance for uninsured individuals.
What insurance does Vanderbilt University Medical Center accept?
Vanderbilt University Medical Center accepts various insurance plans, including BlueCross BlueShield, Aetna, Aetna Better Health (KY Medicaid), and Ambetter of Tennessee (Commercial), as in-network providers. However, Vanderbilt may not participate in all products offered by an insurance carrier. Specific exclusions apply, such as exclusion from Network L & E BlueCross BlueShield TennCare, and out-of-network participation in some plans like Network L. It's crucial to verify your insurance coverage and any specific exclusions or limitations at the Vanderbilt facility where you plan to receive care.
What awards or recognition has Vanderbilt University Medical Center received?
Vanderbilt University Medical Center (VUMC) in Nashville, Tennessee, is a global leader in research, receiving over $1 billion in research funding from external organizations in 2021. This funding supports a wide range of fields including biomedical and biotechnology discoveries, vaccine development, education, and psychology. With more than 3,100 external awards totaling $1,090,386,890, VUMC's funding sources include the National Institutes of Health, the National Science Foundation, the Department of Defense, the Department of Education, and the Centers for Disease Control and Prevention.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.